▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3347 by analyst upside · 2026-08-13
ICUI
ICU Medical, Inc.
Healthcare · Market Cap $4B · P/E 153.3x
ANALYST PRICE TARGET
+7.8%
implied upside to consensus target
Current Price $179.34
Consensus Target $193.38
Bull Target $210.0
Bear Target $178.0
Analysts Covering 8
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
4
Hold
1
Sell
0
52-Week Low $110.51
52-Week High $192.85
YTD Return +29.5%
FUNDAMENTALS
Market Cap $4B
P/E Ratio (TTM) 153.3x
Forward P/E 18.6x
EPS (TTM) $1.17
PEG Ratio 0.10
Dividend Yield N/A
Revenue (TTM) $2.2B
Profit Margin 1.4%
52-WEEK RANGE
52-Week Low $110.51
52-Week High $192.85
Current Price $179.34
Bear Target $178.0
Bull Target $210.0
● Now $179.34 ● Target $193.38
TRADING DATA
Avg Volume 322K
YTD Return +29.5%
Analyst Count 8
Consensus Buy
Upside to Target +7.8%
Last Updated 2026-08-13

ANALYST SUMMARY

ICU Medical, Inc. (ICUI) is currently trading at $179.34 with a Wall Street consensus price target of $193.38, implying potential upside of 7.8% over the next 12 months. 8 analysts currently cover ICUI, with a consensus rating of Buy - 88% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $210.0, while the most cautious has a target of $178.0.

ICUI operates in the Healthcare sector with a market capitalisation of $4B. The stock is up 29.5% year-to-date and is currently trading near the upper end of its 52-week range of $110.51 – $192.85.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

ALKS +11.4%
Alkermes plc
$8B · P/E 128.9x · Buy
TECH -3.5%
Bio-Techne Corporation
$11B · P/E 103.2x · Hold
BMRN +28.6%
BioMarin Pharmaceutical Inc.
$14B · P/E 189.8x · Buy
RGEN +12.1%
Repligen Corporation
$9B · P/E 227.0x · Buy
HAE +5.3%
Haemonetics Corporation
$4B · P/E 44.1x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for ICUI, with each firm's 90-day track record across all stocks we track. See full firm rankings →

BTIG ● Initiated
Buy 2026-06-15 38% win rate (8 calls)
Needham ↑ Upgrade
Hold → Buy 2026-05-27 20% win rate (5 calls)
Keybanc - Reiterated
Overweight → Overweight 2026-04-27 Building track record
Piper Sandler - Reiterated
Overweight → Overweight 2026-04-17 14% win rate (7 calls)
Keybanc - Reiterated
Overweight → Overweight 2026-02-20 Building track record
Piper Sandler - Reiterated
Overweight → Overweight 2026-02-20 14% win rate (7 calls)
Keybanc - Reiterated
Overweight → Overweight 2025-11-07 Building track record
Piper Sandler - Reiterated
Overweight → Overweight 2025-11-07 14% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
65
out of 100
Coverage depth
17/30
Consensus clarity
26/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →